Christoph B. Olivier, Annabel Hölzle/LinkedIn
Mar 13, 2026, 22:05
Christoph B. Olivier: Annabel Hölzle Shared Critical Findings on HALT After TAVR
Christoph B. Olivier, Head of the Clinical Trials Unit, UHZ Freiburg, shared on LinkedIn, adding:
”Congratulations Annabel for an outstanding presentation at the Spring School 2026!
Today Annabel Hölzle shared critical findings from her study: ‘Periprocedural hemostatic and inflammatory changes after TAVR and their association with hypoattenuating leaflet thickening (HALT).’
Her research provides vital clues to improve long-term patient safety in heart valve interventions.
We are very proud to see our team members leading such high-impact clinical discussions.
Great job, Annabel!”
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
-
Apr 23, 2026, 17:57Shalini R: Not All Blood Thinners Are the Same
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran: Navigating the Clinical Complexity of Combined Red Cell Disorders
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved
-
Apr 23, 2026, 17:19Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
-
Apr 23, 2026, 17:18Katarina Ziakova: The WFH Shared Decision – Making Tool Is Driving Critical Conversations in Haemophilia Care
-
Apr 23, 2026, 17:14Paulus Kirchhof: Can We Improve Prevention of Cardiovascular Diseases?
-
Apr 23, 2026, 17:08Wolfgang Miesbach: 5‑Year Gene Therapy Data from WFH Congress 2026
-
Apr 23, 2026, 17:05Veronica Sanchez: The 2026 Guideline on the Management of Dyslipidemia